Abstract
Extensive evidence shows that eNOS is protective in ischemia/reperfusion (I/R) injury. We have shown that triacsin C, a (FACS) inhibitor, increases eNOS activity in the post‐ischemic rat hind limb, suggesting that triacsin C might be useful in treatment of cardiac I/R. Isolated rat hearts, perfused at a constant pressure by the method of Langendorf, were subjected to a 30 minute period of global ischemia, followed by 45 minutes of reperfusion in the presence or absence of 5μM triacsin C.At 45 minutes of reperfusion, LVDP and dP/dt in treated hearts were significantly better than in vehicle controls. Coronary flow and heart rate were not changed by treatment. The infarct area, visualized with 1% 2,3,5‐triphenylterazolium, was significantly smaller in triacsin C treated hearts. The results support the hypothesis, and suggest that FACS inhibitors may represent a new category of drugs for I/R.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
